87 results
8-K
EX-99.1
RLAY
Relay Therapeutics Inc
2 May 24
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
4:10pm
oRLY-2608 + fulvestrant data update in the second half of 2024
oRLY-2608 + fulvestrant + ribociclib initial safety data in the second half of 2024 … clinical trials of its product candidates; Relay Therapeutics’ ability to successfully demonstrate the safety and efficacy of its drug candidates
8-K
EX-99.1
RLAY
Relay Therapeutics Inc
22 Feb 24
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
4:10pm
oRLY-2608 + fulvestrant data update in the second half of 2024
oRLY-2608 + fulvestrant + ribociclib initial safety data in the second half of 2024 … results in connection with future clinical trials of its product candidates; Relay Therapeutics’ ability to successfully demonstrate the safety
8-K
EX-99.1
x5dpm
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
8-K
EX-99.2
hka lgsmv0gxd6ehho
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
424B7
9d7pbgkrcqwkqqcpsj
16 Nov 23
Prospectus with selling stockholder info
4:16pm
8-K
EX-99.1
7du1opzghru8
2 Nov 23
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:10pm
8-K
EX-99.1
fbr9fiv5du3dma
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
8-K
wlqz8bo 0ndapf
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
8-K
EX-99.2
0k4tbjtqt1h76wvplf8y
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
8-K
EX-99.1
wcqlgfxxe0qz6uxgnn6s
8 Aug 23
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
4:14pm
8-K
EX-99.2
ywnp568bfpgnce
8 Aug 23
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
4:14pm
8-K
EX-99.1
0jg8xngjgf ys4
25 May 23
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
5:05pm
8-K
EX-99.1
2wpr3z0xml1ojic3eub
4 May 23
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
4:10pm